ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.81T
Revenue (ttm)	274.45B
Net Income (ttm)	29.52B
Shares Out	20.15M
EPS (ttm)	1,488.44
PE Ratio	60.47
Forward PE	36.46
Dividend	500.00 (0.55%)
Ex-Dividend Date	Dec 27, 2024

Volume	70,624
Average Volume	222,708
Open	91,000
Previous Close	90,000
Day's Range	88,800 - 91,400
52-Week Range	66,600 - 120,800
Beta	0.45
RSI	53.93
Earnings Date	Jul 25, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.